ECTRIMS eLearning

Intra-individual variability in information processing reaction time is a cognitive biomarker of MS
Author(s): ,
M Kasschau
Affiliations:
Neurology, NYU Langone Medical Center, New York
,
G Song
Affiliations:
Stony Brook University, Stony Brook
,
M Shaw
Affiliations:
Neurology, NYU Langone Medical Center, New York
,
M Porter
Affiliations:
New York Institute of Technology College of Osteopathic Medicine, Old Westbury, NY, United States
L Charvet
Affiliations:
Neurology, NYU Langone Medical Center, New York
ECTRIMS Learn. Charvet L. 09/14/16; 145490; EP1394
Leigh E. Charvet
Leigh E. Charvet
Contributions
Abstract

Abstract: EP1394

Type: ePoster

Abstract Category: Clinical aspects of MS - Clinical assessment tools

Cognitive impairment remains a challenging symptom in MS to both detect and ameliorate. Sensitive and reliable measures are needed to identify cognitive involvement at its earliest stages and its link to disease activity. Intra-individual variability (IIV) in information processing reaction time can be easily and precisely measured through administration of computer-based attention tasks to provide an index of consistency that is independent from overall speed or accuracy. Here, we measured IIV using the Attention Network Test- Interaction (ANT-I, measuring Alerting, Orienting and Executive components of attention) along with standard neuropsychological measures (Symbol Digit Modalities Test or SDMT and learning trails for the Brief Visual Memory Test- Revised or BVMT-R and Rey Auditory Verbal Learning Test or RAVLT, approximating the BICAMS) in a group of n=106 MS patients and n=66 healthy control subjects. ANT-I IIV significantly correlated with the SDMT (p< 0.01) and EDSS (p< 0.001). We then compared performances in those with earliest disease (n=32, ≤35 years in age, median EDSS 2.0). Across all measures, only ANT-I IIV and BVMT-R significantly predicted MS group membership (r=0.29 and 0.35, respectively). IIV correctly classified 68.4% of the MS participants, including in those with BICAMS performance within normal limits. IIV is a sensitive marker of cognitive involvement in MS at in its earliest stages and may serve as an important outcome measure for interventions aimed at preventing cognitive decline.

Disclosure:

Margaret Kasschau: Nothing to disclose

Ge Song: Nothing to disclose

Michael Shaw: Nothing to disclose

Michael Porter: Nothing to disclose

Leigh Charvet: Consultant for Biogen

Abstract: EP1394

Type: ePoster

Abstract Category: Clinical aspects of MS - Clinical assessment tools

Cognitive impairment remains a challenging symptom in MS to both detect and ameliorate. Sensitive and reliable measures are needed to identify cognitive involvement at its earliest stages and its link to disease activity. Intra-individual variability (IIV) in information processing reaction time can be easily and precisely measured through administration of computer-based attention tasks to provide an index of consistency that is independent from overall speed or accuracy. Here, we measured IIV using the Attention Network Test- Interaction (ANT-I, measuring Alerting, Orienting and Executive components of attention) along with standard neuropsychological measures (Symbol Digit Modalities Test or SDMT and learning trails for the Brief Visual Memory Test- Revised or BVMT-R and Rey Auditory Verbal Learning Test or RAVLT, approximating the BICAMS) in a group of n=106 MS patients and n=66 healthy control subjects. ANT-I IIV significantly correlated with the SDMT (p< 0.01) and EDSS (p< 0.001). We then compared performances in those with earliest disease (n=32, ≤35 years in age, median EDSS 2.0). Across all measures, only ANT-I IIV and BVMT-R significantly predicted MS group membership (r=0.29 and 0.35, respectively). IIV correctly classified 68.4% of the MS participants, including in those with BICAMS performance within normal limits. IIV is a sensitive marker of cognitive involvement in MS at in its earliest stages and may serve as an important outcome measure for interventions aimed at preventing cognitive decline.

Disclosure:

Margaret Kasschau: Nothing to disclose

Ge Song: Nothing to disclose

Michael Shaw: Nothing to disclose

Michael Porter: Nothing to disclose

Leigh Charvet: Consultant for Biogen

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies